Christopher R. Gibson

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance

Barbara J. Ring, Jenny Y. Chien, Kimberly K. Adkison et al. · Journal of Pharmaceutical Sciences · 2011 · 198 citations

Pharmacokinetic Modeling, Medicine, Drug Discovery +8

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones et al. · Journal of Pharmaceutical Sciences · 2011 · 170 citations

Precision Dosing, Physiologically Based Pharmacokinetics, Pharmacokinetic Modeling +9

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design

Marc L. Reitman, Xiaoyan Chu, Xiaoxin Cai et al. · Clinical Pharmacology & Therapeutics · 2010 · 156 citations

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution

Rhys D.O. Jones, Hannah M. Jones, Malcolm Rowland et al. · Journal of Pharmaceutical Sciences · 2011 · 133 citations

Translational Medicine, Pharmacokinetic Modeling, Part 2 +11

IgG2m4, an engineered antibody isotype with reduced Fc function

Zhiqiang An, Gail Forrest, Renée Moore et al. · mAbs · 2009 · 97 citations · Full text